Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report

Table 1 Studies of epidermal growth factor receptor-tyrosine kinase inhibitors response for delE709_T710insD

Ref.	Patient No.	Gender	Age (yr)	Smoking	Stage	Histologic type	TKI used/line	Response	PFS (m)	OS (m)
Wu et al[7], 2011	1	F	61	No	IV	AD	Gefitinib/NA	SD	5.1	22.7
	2	M	65	Yes	IV	AD	Gefitinib/NA	PD	0.9	11.1
Ackerman et al[9], 2012	3	F	88	No	IV	AD	Erlotinib/1st	PR	6	NA
Kobayashi et al[19], 2015	4	M	63	NA	IV	AD	Erlotinib/3rd	SD	NA	NA
							Afatinib/4th	PR	NA
Wu et al[6], 2016	5	F	57	No	IV	AD	Gefitinib/NA	PD	0.6	24.1
	6	M	79	Yes	IV	AD	Gefitinib/NA	SD	6.2	6.2
	7	M	68	Yes	IV	AD	Gefitinib/NA	PD	2.3	29.5
Klughammer et al[10], 2016	8	F	50	No	III/IV	NSCLC	Erlotinib/2nd	PD	1.3	1.7
Ibrahim et al[13], 2017	9	F	52	No	IV	AD	Afatinib/1st	PR	NA	NA
An et al[14], 2019	10	M	56	No	IV	AD	Afatinib/2nd	PR	11	More than 21
Iwamoto et al[15], 2019	11	F	56	No	IV	AD	Afatinib/6th	PR	7	NA
D’Haene et al[16], 2019	12	F	57	No	III	AD	Afatinib/2nd	PR	12	36
Martin et al[11], 2019	13	M	60	No	IV	AD	Erlotinib/NA	PD	1	3
Isaksson et al[12], 2020	14	NA	NA	NA	IV	NA	Erlotinib/1st	PD	8	NA
Sousa et al[8], 2020	15	F	66	Yes	IV	AD	Gefitinib/1st	PD	3	24
	16	F	46	Yes	II	AD	Erlotinib/2nd	PD	4	26
	17	F	57	No	IV	AD	Erlotinib/2nd	PD	3	18
Wei et al[17], 2021	18	F	70	No	II	NSCLC	Afatinib/1st	PR	23	On going
Jelli et al[18], 2021	19	F	57	No	IV	AD	Afatinib/1st	CR	17 (On going)	17 (On going)
Xu et al, 2021 (this case)	20	F	56	No	IV	AD	Dacomitinib/2nd	PR	7	On going

F: Female; M: Male; NA: Data not-available; PFS: Progression-free survival; OS: Overall survival; TKI: Tyrosine kinase inhibitor; AD: Lung adenocarcinoma; NSCLC: Non-small cell lung cancer; PR: Partial response; SD: Stable disease; PD: Progression disease.